- Home
- ANL vs CNTB Comparison
ANL vs CNTB Comparison
Compare ANL & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- CNTB
- Stock Information
- Founded
- ANL 2004
- CNTB 2012
- Country
- ANL Cayman Islands
- CNTB United States
- Employees
- ANL N/A
- CNTB N/A
- Industry
- ANL
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- CNTB Health Care
- Exchange
- ANL Nasdaq
- CNTB Nasdaq
- Market Cap
- ANL 56.0M
- CNTB 54.4M
- IPO Year
- ANL 2023
- CNTB 2021
- Fundamental
- Price
- ANL $1.45
- CNTB $2.00
- Analyst Decision
- ANL Hold
- CNTB Strong Buy
- Analyst Count
- ANL 1
- CNTB 2
- Target Price
- ANL N/A
- CNTB $7.50
- AVG Volume (30 Days)
- ANL 6.9K
- CNTB 285.3K
- Earning Date
- ANL 08-12-2025
- CNTB 09-04-2025
- Dividend Yield
- ANL N/A
- CNTB N/A
- EPS Growth
- ANL N/A
- CNTB N/A
- EPS
- ANL N/A
- CNTB N/A
- Revenue
- ANL N/A
- CNTB $26,033,000.00
- Revenue This Year
- ANL N/A
- CNTB N/A
- Revenue Next Year
- ANL N/A
- CNTB N/A
- P/E Ratio
- ANL N/A
- CNTB N/A
- Revenue Growth
- ANL N/A
- CNTB N/A
- 52 Week Low
- ANL $1.10
- CNTB $0.51
- 52 Week High
- ANL $3.89
- CNTB $2.86
- Technical
- Relative Strength Index (RSI)
- ANL 44.72
- CNTB 59.15
- Support Level
- ANL $1.48
- CNTB $1.70
- Resistance Level
- ANL $1.55
- CNTB $2.45
- Average True Range (ATR)
- ANL 0.04
- CNTB 0.36
- MACD
- ANL -0.00
- CNTB -0.02
- Stochastic Oscillator
- ANL 25.00
- CNTB 42.51
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.